by Researchers from Odense University Hospital and the University of Southern Denmark have developed an innovative blood test that can detect genetic diseases in fetuses. The test, called desNIPT, analyzes the genes in the fetus using a blood sample from the expectant mother. The results of the study, published in the New England Journal of Medicine, showed that desNIPT effectively identified alterations in fetal genes, which are a leading cause of severe congenital diseases.
Traditionally, identifying genetic syndromes in unborn children would require invasive procedures such as chorionic villus sampling or amniocentesis. However, desNIPT offers a simpler and non-invasive alternative. By analyzing fetal DNA found in the mother’s bloodstream, desNIPT can accurately screen for the majority of known serious genetic syndromes.
The desNIPT test represents an evolution of the first-generation Non-Invasive Prenatal Test (NIPT) method, improving upon it with significant advancements. NIPT is already used to screen for chromosomal disorders like Down syndrome, but desNIPT takes it a step further by examining all genes within the fetal genome. This approach, known as exome sequencing, is currently only used in pregnancies where abnormalities are detected during ultrasound scans.
The sensitivity of desNIPT allows for the detection of genetic abnormalities even when the amount of fetal DNA in the mother’s blood is minimal. This is a major advancement as many congenital diseases arise from subtle modifications in fetal DNA. The test successfully identified newly arising disease-causing alterations in 11 out of 36 pregnancies, showing comparable effectiveness to invasive procedures like chorionic villus sampling or amniocentesis.
The potential of the desNIPT test goes beyond the detection of known genetic diseases. It opens the possibility of screening for a broader range of genetic disorders, including those that cannot be revealed through ultrasound scans. This could significantly improve the accuracy of prenatal screening and lead to earlier diagnoses and interventions.
The researchers believe that desNIPT has significant potential as a screening tool in conjunction with ultrasound examinations, which are the current standard for all pregnant women. By combining the two methods, a more comprehensive screening can be achieved, reducing the need for follow-up diagnostic examinations.
The study showed promising results, with no false-positive results observed. However, as a proof-of-concept study, further validation in a larger study is needed before desNIPT can be made widely available to pregnant women. The researchers are focused on refining and scaling the methodology to ensure the accuracy and reliability of the test.
In conclusion, the development of the desNIPT blood test represents a significant advancement in prenatal screening for genetic diseases. By offering a non-invasive and comprehensive approach, it has the potential to improve the early detection and management of fetal disorders. Further research and validation are needed to bring this innovative test to pregnant women worldwide.
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.
